TAPTIQOM

Posology Recommended therapy is one eye drop in the conjunctival sac of the affected eye(s) once daily. If one dose is missed, treatment should continue with the next dose as planned. The dose should not exceed one drop in the affected eye(s) daily.

Taptiqom is a preservative free sterile solution packaged in a single-dose container. For single use only, one container is sufficient to treat both eyes. Any unused solution should be discarded immediately after use. Paediatric population The safety and efficacy of Taptiqom in children and adolescents below the age of 18 years have not been established.

No data are available. Taptiqom is not recommended for use in children and adolescents below the age of 18 years. Use in elderly No dosage alteration in elderly patients is necessary. Use in renal/hepatic impairment Tafluprost and timolol eye drops have not been studied in patients with renal/hepatic impairment and Taptiqom should therefore be used with caution in such patients.

Method of administration Ocular use To reduce the risk of darkening of the eyelid skin the patients should wipe off any excess solution from the skin. When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the systemic absorption is reduced.

This may result in a decrease in systemic side effects and an increase of local activity. If more than one topical ophthalmic medicinal product is being used, each one should be administered at least 5 minutes apart. Contact lenses should be removed before instillation of the eye drops and may be reinserted after 15 minutes.

Patients should be instructed to avoid allowing the container to come into contact with the eye or surrounding structures as this could cause injury to the eye (see instructions for use). Patients should also be instructed that ocular solutions, if handled improperly, can become contaminated by common bacteria known to cause ocular infections.

Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.

In clinical studies, over 484 patients have been treated with Taptiqom. The most frequently reported treatment-related adverse event was conjunctival/ocular hyperaemia. 2% of patients. The adverse reactions reported in the clinical studies using Taptiqom were limited to those earlier reported for either of the single active substances tafluprost or timolol.

No new adverse reactions specific for Taptiqom were observed in the clinical studies. The majority of adverse reactions reported were ocular, mild or moderate in severity and none were serious. Like other topically applied ophthalmic agents, tafluprost and timolol are absorbed systemically.

This may cause similar undesirable effects as seen with systemic beta-blocking agents. Incidence of systemic adverse reactions after topical ophthalmic administration is lower than for systemic administration. Listed adverse reactions include reactions seen within the class of ophthalmic beta-blockers.

The following adverse reactions have been reported with Taptiqom during clinical trials (within each frequency grouping, adverse reactions are presented in order of decreasing frequency). The frequency of possible adverse reactions listed below is defined using the following convention: Very common ≥1/10 Common ≥1/100 to <1/10 Uncommon ≥1/1,000 to <1/100 Rare ≥1/10,000 to <1/1,000 Very rare <1/10,000 Not known Frequency cannot be estimated from the available data Taptiqom (Tafluprost/timolol combination) System Organ Class Frequency Adverse Reactions Nervous system disorders Uncommon Headache.

Eye disorders Common Conjunctival/ocular hyperaemia, eye pruritus, eye pain, change of eyelashes (increased length, thickness and number of lashes), eyelash discolouration, eye irritation, foreign body sensation in eyes, blurred vision, photophobia.

Uncommon Abnormal sensation in eye, dry eye, ocular discomfort, conjunctivitis, erythema of eyelid, eye allergy, eyelid oedema, superficial punctate keratitis, lacrimation increased, anterior chamber inflammation, asthenopia, blepharitis.

Additional adverse reactions that have been seen with either of the active substances (tafluprost or timolol), and may potentially occur also with Taptiqom are listed below: Tafluprost System Organ Class Adverse Reactions Eye disorders Reduced visual acuity, increased iris pigmentation , blepharal pigmentation, conjunctival oedema, eye discharge, anterior chamber cell, anterior chamber flare, allergic conjunctivitis, conjunctival pigmentation, conjunctival follicles, deepening of eye lid sulcus, iritis/uveitis, macular oedema/cystoid macular oedema.

Skin and subcutaneous tissue disorders Hypertrichosis of eyelid. Respiratory disorders Exacerbation of asthma, dyspnoea. Timolol System Organ Class Adverse Reactions Immune system disorders Signs and symptoms of allergic reactions including angioedema, urticaria, localized and generalized rash, anaphylaxis, pruritus.

Metabolism and nutrition disorders Hypoglycaemia. Psychiatric disorders Depression, insomnia, nightmares, memory loss, nervousness, hallucination. Nervous system disorders Dizziness, syncope, paraesthesia, increase in signs and symptoms of myasthenia gravis, cerebrovascular accident, cerebral ischaemia.

4), tearing, corneal erosion. Ear and labyrinth disorders Tinnitus. Cardiac disorders Bradycardia, chest pain, palpitation, oedema, arrhythmia, congestive heart failure, cardiac arrest, heart block, atrioventricular block, cardiac failure.

Vascular disorders Hypotension, claudication, Raynaud’s phenomenon, cold hands and feet. Respiratory, thoracic, and mediastinal disorders Dyspnoea, bronchospasm (predominantly in patients with pre-existing bronchospastic disease), respiratory failure, cough.

Gastrointestinal disorders Nausea, dyspepsia, diarrhoea, dry mouth, dysgeusia, abdominal pain, vomiting. Skin and subcutaneous tissue disorders Alopecia, psoriasiform rash or exacerbation of psoriasis, skin rash. Musculoskeletal and connective tissue disorders Systemic lupus erythematosus, myalgia, arthropathy.

Reproductive system and breast disorders Peyronie’s disease, decreased libido, sexual dysfunction. General disorders and administration site conditions Asthenia/fatigue, thirst. Cases of corneal calcification have been reported very rarely in association with the use of phosphate containing eye drops in some patients with significantly damaged corneas.

Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Systemic effects:

Like other topically applied ophthalmic agents, tafluprost and timolol are absorbed systemically. Due to the beta-adrenergic component timolol, the same types of cardiovascular, pulmonary and other adverse reactions as seen with systemic beta- adrenergic blocking agents may occur.

Incidence of systemic adverse reactions after topical ophthalmic administration is lower than for systemic administration. 2. g. coronary heart disease, Prinzmetal's angina and cardiac failure) and hypotension, therapy with beta-blockers should be critically assessed and the therapy with other active substances should be considered.

Patients with cardiovascular diseases should be watched for signs of deterioration of these diseases and of adverse reactions. Due to its negative effect on conduction time, beta-blockers should only be given with caution to patients with first degree heart block.

e. severe forms of Raynaud's disease or Raynaud's syndrome) should be treated with caution.

Respiratory disorders:

Respiratory reactions, including death due to bronchospasm in patients with asthma have been reported following administration of some ophthalmic beta-blockers. Taptiqom should be used with caution, in patients with mild/moderate chronic obstructive pulmonary disease (COPD) and only if the potential benefit outweighs the potential risk.

Hypoglycemia/diabetes:

Beta-blockers should be administered with caution in patients subject to spontaneous hypoglycaemia or to patients with labile diabetes, as beta-blockers may mask the signs and symptoms of acute hypoglycaemia. Beta-blockers may also mask the signs of hyperthyroidism.

Abrupt withdrawal of beta-blocker therapy may precipitate a worsening of symptoms.

Corneal diseases:

Ophthalmic beta-blockers may induce dryness of eyes. Patients with corneal diseases should be treated with caution.

Other beta-blocking agents:

The effect on intra-ocular pressure or the known effects of systemic beta-blockade may be potentiated when timolol (a component of Taptiqom) is given to the patients already receiving a systemic beta-blocking agent. The response of these patients should be closely observed.

The use of two topical β-adrenergic blocking agents is not recommended.

Angle-closure glaucoma:

In patients with angle-closure glaucoma, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil with a miotic. Timolol has little or no effect on the pupil. When timolol is used to reduce elevated intraocular pressure in angle-closure glaucoma it should be used with a miotic and not alone.

Anaphylactic reactions:

While taking beta-blockers, patients with a history of atopy or a history of severe anaphylactic reaction to a variety of allergens may be more reactive to repeated challenge with such allergens and unresponsive to the usual doses of adrenaline used to treat anaphylactic reactions.

g. timolol, acetazolamide) after filtration procedures. g. of adrenaline. The anaesthesiologist should be informed when the patient is receiving timolol. Before treatment is initiated, patients should be informed of the possibility of eyelash growth, darkening of the eyelid skin and increased iris pigmentation which are related to tafluprost therapy.

Some of these changes may be permanent, and may lead to differences in appearance between the eyes when only one eye is treated. The change in iris pigmentation occurs slowly and may not be noticeable for several months. g. blue-brown, grey-brown, yellow-brown and green-brown.

The risk of lifelong heterochromia between the eyes in unilateral cases is obvious. There is a potential for hair growth to occur in areas where tafluprost solution comes repeatedly in contact with the skin surface. There is no experience with tafluprost in neovascular, angle-closure, narrow-angle or congenital glaucoma.

There is only limited experience with tafluprost in aphakic patients and in pigmentary or pseudoexfoliative glaucoma. Caution is recommended when using tafluprost in aphakic patients, pseudophakic patients with torn posterior lens capsule or anterior chamber lenses, or in patients with known risk factors for cystoid macular oedema or iritis/uveitis.

1 . Reactive airway disease including bronchial asthma, or a history of bronchial asthma, severe chronic obstructive pulmonary disease. Sinus bradycardia, sick sinus syndrome, including sino-atrial block, second or third degree atrioventricular block not controlled with pace-maker.

Overt cardiac failure, cardiogenic shock.